查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1769726

2025年全球紫斑治疗市场报告

Purpura Treatment Global Market Report 2025
出版日期: | 出版商: The Business Research Company | 英文 175 Pages | 商品交期: 2-10个工作天内

价格
简介目录

预计未来几年紫斑治疗市场规模将强劲成长。 2029年，该市场规模将成长至21.2亿美元，复合年增长率为8.7%。未来市场发展的驱动力将包括：生物疗法的发展、基因筛检需求的不断增长、对远端医疗进行早期诊断的日益依赖、罕见疾病治疗的监管激励措施以及向个人化治疗方法的转变。预测期内的主要趋势包括基因治疗方法的进步、细胞疗法的创新、精准药物传输技术、穿戴式诊断工具的普及以及基于奈米技术的医学的进步。

自体免疫疾病的日益普及预计将推动紫斑治疗市场的扩张。当人类免疫系统将自体健康细胞和组织误认为有害入侵者（例如细菌或病毒）时，就会引发自体免疫疾病。环境因素通常会促进发炎和分子模拟，从而导致免疫系统攻击自身组织，增加自体免疫疾病的风险。紫斑治疗在自体免疫疾病的管理中发挥关键作用，它可以抑制过度的免疫反应，促进血小板生成，并减少血管发炎。这有助于减轻瘀伤、出血和血小板计数低等症状，这些症状在自体免疫免疫性血小板缺乏紫斑症(ITP)）中很常见。例如，根据英国政府部门健康改善与差异办公室2023年3月发布的报告，2022年16岁以上人群中17.6%报告患有长期肌肉骨骼系统（MSK）疾病，高于2021年的17.0%。因此，自体免疫疾病盛行率的上升正在推动紫斑治疗市场的成长。

个人化医疗需求的不断增长也有望推动紫斑治疗市场的发展。个人化医疗是指根据患者的遗传易感性、环境因素和生活方式，为其量身定制治疗方案和干预措施。基因组学和生物技术的进步推动了这一需求，使得根据个别基因图谱进行更精准、更有效的治疗成为可能，最终改善患者预后并最大限度地减少副作用。在紫斑治疗领域，个人化医疗利用基因和免疫系统数据来客製化治疗方案，根据患者独特的生物反应提高疗效并减少副作用。例如，根据美国专业会员组织个人化医疗联盟 (Coalition for Personalized Medicine) 的数据，到 2022 年，新核准的12 种个人化医疗将占当年所有新核准治疗方法的约 34%，较前几年显着成长。因此，人们对个人化医疗日益增长的兴趣正在推动紫斑治疗市场的扩张。

目录

第一章执行摘要

第二章 市场特征

第三章 市场趋势与策略

第四章 市场：宏观经济情景，包括利率、通膨、地缘政治、贸易战和关税，以及新冠疫情和復苏对市场的影响

第五章 全球成长分析与策略分析框架

  • 全球紫斑治疗：PESTEL分析（政治、社会、技术、环境、法律因素、驱动因素与限制因素）
  • 最终用途产业分析
  • 全球紫斑治疗市场：成长率分析
  • 全球紫斑治疗市场表现：规模与成长，2019-2024 年
  • 全球紫斑治疗市场预测：2024-2029 年及 2034 年规模与成长
  • 全球紫斑治疗：总目标市场（TAM）

第六章市场区隔

  • 全球紫斑治疗市场：依类型、绩效及预测，2019-2024 年、2024-2029 年、2034 年
  • 非血小板减少性紫斑
  • 血小板减少性紫斑
  • 过敏性紫斑
  • 全球紫斑治疗市场（依治疗类型、表现及预测），2019-2024 年、2024-2029 年、2034 年
  • 局部治疗
  • 口服药物
  • 玻璃体内注射
  • 雷射治疗
  • 动态疗法
  • 全球紫斑治疗市场（依病例、绩效及预测），2019-2024 年、2024-2029 年、2034 年
  • 急性
  • 慢性的
  • 全球紫斑治疗市场：依通路、绩效及预测，2019-2024 年、2024-2029 年、2034 年
  • 医院药房
  • 网路药局
  • 零售药局
  • 全球紫斑治疗市场：按最终用户、绩效和预测，2019-2024 年、2024-2029 年、2034 年
  • 医院
  • 诊所
  • 其他最终用户
  • 全球紫斑治疗市场依非血小板减少性紫斑症类型细分、绩效及预测（2019-2024 年、2024-2029 年及 2034 年）
  • 特发性紫斑
  • 老年性紫斑
  • 紫斑性血管异常
  • 全球紫斑治疗市场依血小板减少性紫斑症疾病类型细分，绩效及预测，2019-2024 年、2024-2029 年、2034 年
  • 免疫性血小板减少性紫斑症（ITP）
  • 药物性血小板减少性紫斑
  • 次发性紫斑
  • 全球紫斑治疗市场按过敏性紫斑症类型细分、绩效及预测，2019-2024 年、2024-2029 年、2034 年
  • 药物性过敏性紫斑
  • 食物引起的过敏性紫斑
  • 感染相关过敏性紫斑

第七章 区域和国家分析

  • 全球紫斑治疗市场：依地区、绩效及预测，2019-2024 年、2024-2029 年、2034 年
  • 全球紫斑治疗市场：依国家、地区、绩效及预测，2019-2024 年、2024-2029 年、2034 年

第八章 亚太市场

第九章：中国市场

第十章 印度市场

第十一章 日本市场

第十二章 澳洲市场

第十三章 印尼市场

第十四章 韩国市场

第十五章 西欧市场

第十六章英国市场

第十七章 德国市场

第十八章 法国市场

第十九章：义大利市场

第20章：西班牙市场

第21章 东欧市场

第22章 俄罗斯市场

第23章 北美市场

第24章美国市场

第25章：加拿大市场

第26章 南美洲市场

第27章：巴西市场

第28章 中东市场

第29章：非洲市场

第30章竞争格局与公司概况

  • 紫斑治疗市场：竞争格局
  • 紫斑治疗市场：公司简介
    • Merck & Co Inc. Overview, Products and Services, Strategy and Financial Analysis
    • Sanofi SA Overview, Products and Services, Strategy and Financial Analysis
    • GlaxoSmithKline plc Overview, Products and Services, Strategy and Financial Analysis
    • Takeda Pharmaceutical Company Limited Overview, Products and Services, Strategy and Financial Analysis
    • Amgen Inc. Overview, Products and Services, Strategy and Financial Analysis

第31章 其他大型创新企业

  • CSL Limited
  • Intas Pharmaceuticals Ltd.
  • Biogen Inc.
  • Chugai Pharmaceutical Co Ltd.
  • Sun Pharmaceutical Industries Limited
  • Octapharma AG
  • Grifols SA
  • GC Pharma
  • Emergent BioSolutions Inc.
  • Kissei Pharmaceutical Co Ltd.
  • Ablynx NV
  • Shire plc
  • Lee's Pharmaceutical Holdings Limited
  • Omeros Corporation
  • KM Biologics Co Ltd.

第 32 章全球市场竞争基准化分析与仪表板

第33章 重大併购

第34章近期市场趋势

第 35 章 高市场潜力国家、细分市场与策略

  • 2029年紫斑治疗市场：提供新机会的国家
  • 2029 年紫斑治疗市场：细分领域带来新机会
  • 2029 年紫斑症治疗市场：成长策略
    • 基于市场趋势的策略
    • 竞争对手的策略

第36章 附录

简介目录
Product Code: r36043

Purpura treatment refers to the medical care and management of purpura, which are purple-colored spots or patches on the skin caused by small blood vessels leaking under the skin. Purpura treatment is utilized by healthcare providers to manage symptoms and address underlying conditions such as platelet disorders, infections, or autoimmune diseases that cause bleeding under the skin.

The main types of purpura treatment include non-thrombocytopenic purpura, thrombocytopenic purpura, and allergic purpura. Non-thrombocytopenic purpura is characterized by bleeding under the skin, resulting in red or purple discoloration (purpura). These conditions are managed through different treatment approaches, such as topical therapies, oral medications, intravitreal injections, laser treatments, and photodynamic therapy. Purpura may present as either acute or chronic cases and is distributed through several channels, including hospital pharmacies, online pharmacies, and retail pharmacies. The treatments are utilized by various end users, such as hospitals, clinics, and other healthcare facilities.

The purpura treatment market research report is one of a series of new reports from The Business Research Company that provides purpura treatment market statistics, including purpura treatment industry global market size, regional shares, competitors with a purpura treatment market share, purpura treatment market segments, market trends and opportunities, and any further data you may need to thrive in the purpura treatment industry. This purpura treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The purpura treatment market size has grown strongly in recent years. It will grow from $1.39 billion in 2024 to $1.51 billion in 2025 at a compound annual growth rate (CAGR) of 9.1%. The historical growth has been driven by the introduction of new therapeutic options, increased use of corticosteroids, growth in clinical research initiatives, rising healthcare expenditure, and improvements in hospital facilities.

The purpura treatment market size is expected to see strong growth in the next few years. It will grow to $2.12 billion in 2029 at a compound annual growth rate (CAGR) of 8.7%. Future market expansion will be fueled by the development of biologic therapies, rising demand for genetic screening, increased reliance on telehealth for early diagnosis, regulatory incentives for rare disease treatments, and a shift toward customized treatment approaches. Key trends anticipated during the forecast period include progress in gene-based therapies, innovations in cell therapy, precision drug delivery technologies, adoption of wearable diagnostic tools, and advancements in nanotechnology-based medicine.

The growing prevalence of autoimmune diseases is expected to drive the expansion of the purpura treatment market. Autoimmune diseases occur when the body's immune system mistakenly attacks its own healthy cells and tissues, believing they are harmful invaders such as bacteria or viruses. Environmental triggers often contribute to this by promoting inflammation or molecular mimicry, which leads the immune system to attack the body's own tissues and increases the risk of autoimmune diseases. Treatments for purpura play a crucial role in managing autoimmune diseases by suppressing the overactive immune response, enhancing platelet production, and reducing inflammation in blood vessels. This helps control symptoms like bruising, bleeding, and low platelet counts, which are commonly seen in autoimmune-related purpura such as immune thrombocytopenic purpura (ITP). For example, in March 2023, a report published by the Office for Health Improvement & Disparities, a UK government department, stated that in 2022, 17.6% of individuals aged 16 and above reported having a long-term musculoskeletal (MSK) condition, an increase from 17.0% in 2021. Thus, the rise in autoimmune disease prevalence is fueling the growth of the purpura treatment market.

The increasing demand for personalized medicine is also expected to boost the purpura treatment market. Personalized medicine involves tailoring medical treatments and practices to individual patients based on their genetic makeup, environmental factors, and lifestyle. This demand is being driven by advances in genomics and biotechnology, which allow for more precise and effective treatments tailored to individual genetic profiles, ultimately improving patient outcomes and minimizing side effects. In the context of purpura, personalized medicine uses genetic and immune system data to customize therapies, thereby improving treatment effectiveness and reducing adverse effects for patients based on their unique biological responses. For instance, according to the Personalized Medicine Coalition, a U.S.-based professional membership organization, in 2022, 12 newly approved personalized medicines accounted for approximately 34% of all new therapies approved that year, reflecting significant growth from previous years. Therefore, the growing interest in personalized medicine is contributing to the expansion of the purpura treatment market.

Leading companies in the purpura treatment market are prioritizing advancements in therapeutic options such as oral spleen tyrosine kinase (SYK) inhibitors to enhance treatment outcomes. These oral SYK inhibitors are medications that block the SYK enzyme, which plays a key role in the immune system's signaling processes. For example, in April 2023, Kissei Pharmaceutical Co., Ltd., a pharmaceutical company based in Japan, introduced TAVALISSE tablets (100 mg and 150 mg) in Japan as an oral treatment for adult patients with chronic idiopathic thrombocytopenic purpura (ITP). TAVALISSE (fostamatinib sodium hydrate) works by inhibiting the destruction of platelets by macrophages, thus improving bleeding symptoms in chronic ITP patients. It was approved in Japan following a Phase 3 clinical trial (R788-1301), where 36% of patients achieved a stable platelet response compared to 0% in the placebo group, demonstrating its effectiveness as a new treatment option.

Major players in the purpura treatment market are Merck & Co Inc., Sanofi S.A., GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Amgen Inc., CSL Limited, Intas Pharmaceuticals Ltd., Biogen Inc., Chugai Pharmaceutical Co Ltd., Sun Pharmaceutical Industries Limited, Octapharma AG, Grifols S.A., GC Pharma, Emergent BioSolutions Inc., Kissei Pharmaceutical Co Ltd., Ablynx N.V., Shire plc, Lee's Pharmaceutical Holdings Limited, Omeros Corporation, and KM Biologics Co Ltd.

North America was the largest region in the purpura treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in purpura treatment report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the purpura treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The purpura treatment market consists of revenues earned by entities by providing services such as diagnostic evaluations, immunosuppressive therapy, intravenous immunoglobulin (IVIG) infusions, platelet transfusions, and supportive care. The market value includes the value of related goods sold by the service provider or included within the service offering. The purpura treatment market also includes sales of products including corticosteroids, immunoglobulins (IVIG), biologics, immunosuppressants, and diagnostic kits. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Purpura Treatment Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on purpura treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
  • Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for purpura treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The purpura treatment market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

  • Markets Covered:1) By Type: Non-Thrombocytopenic Purpura; Thrombocytopenic Purpura; Allergic Purpura
  • 2) By Treatment Type: Topical Treatments; Oral Medications; Intravitreal Injections; Laser Therapy; Photodynamic Therapy
  • 3) By Cases: Acute; Chronic
  • 4) By Distribution Channel: Hospital Pharmacy; Online Pharmacy; Retail Pharmacy
  • 5) By End-User: Hospitals; Clinics; Other End-Users
  • Subsegments:
  • 1) By Non-Thrombocytopenic Purpura: Idiopathic Purpura; Senile Purpura; Vascular Abnormalities
  • 2) By Thrombocytopenic Purpura: Immune Thrombocytopenic Purpura (ITP); Drug-induced Thrombocytopenic Purpura; Secondary Thrombocytopenic Purpura
  • 3) By Allergic Purpura: Drug-induced Allergic Purpura; Food-induced Allergic Purpura; Infectious-related Allergic Purpura
  • Companies Mentioned: Merck & Co Inc.; Sanofi S.A.; GlaxoSmithKline plc; Takeda Pharmaceutical Company Limited; Amgen Inc.
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Purpura Treatment Market Characteristics

3. Purpura Treatment Market Trends And Strategies

4. Purpura Treatment Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Purpura Treatment Growth Analysis And Strategic Analysis Framework

  • 5.1. Global Purpura Treatment PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
  • 5.2. Analysis Of End Use Industries
  • 5.3. Global Purpura Treatment Market Growth Rate Analysis
  • 5.4. Global Purpura Treatment Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
  • 5.5. Global Purpura Treatment Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
  • 5.6. Global Purpura Treatment Total Addressable Market (TAM)

6. Purpura Treatment Market Segmentation

  • 6.1. Global Purpura Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Non-Thrombocytopenic Purpura
  • Thrombocytopenic Purpura
  • Allergic Purpura
  • 6.2. Global Purpura Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Topical Treatments
  • Oral Medications
  • Intravitreal Injections
  • Laser Therapy
  • Photodynamic Therapy
  • 6.3. Global Purpura Treatment Market, Segmentation By Cases, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Acute
  • Chronic
  • 6.4. Global Purpura Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Hospital Pharmacy
  • Online Pharmacy
  • Retail Pharmacy
  • 6.5. Global Purpura Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Hospitals
  • Clinics
  • Other End-Users
  • 6.6. Global Purpura Treatment Market, Sub-Segmentation Of Non-Thrombocytopenic Purpura, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Idiopathic Purpura
  • Senile Purpura
  • Purpura Vascular Abnormalities
  • 6.7. Global Purpura Treatment Market, Sub-Segmentation Of Thrombocytopenic Purpura, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Immune Thrombocytopenic Purpura (ITP)
  • Drug-induced Thrombocytopenic Purpura
  • Secondary Thrombocytopenic Purpura
  • 6.8. Global Purpura Treatment Market, Sub-Segmentation Of Allergic Purpura, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Drug-Induced Allergic Purpura
  • Food-Induced Allergic Purpura
  • Infectious-related Allergic Purpura

7. Purpura Treatment Market Regional And Country Analysis

  • 7.1. Global Purpura Treatment Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 7.2. Global Purpura Treatment Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Purpura Treatment Market

  • 8.1. Asia-Pacific Purpura Treatment Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Purpura Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.3. Asia-Pacific Purpura Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.4. Asia-Pacific Purpura Treatment Market, Segmentation By Cases, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Purpura Treatment Market

  • 9.1. China Purpura Treatment Market Overview
  • 9.2. China Purpura Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.3. China Purpura Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.4. China Purpura Treatment Market, Segmentation By Cases, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Purpura Treatment Market

  • 10.1. India Purpura Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.2. India Purpura Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.3. India Purpura Treatment Market, Segmentation By Cases, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Purpura Treatment Market

  • 11.1. Japan Purpura Treatment Market Overview
  • 11.2. Japan Purpura Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.3. Japan Purpura Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.4. Japan Purpura Treatment Market, Segmentation By Cases, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Purpura Treatment Market

  • 12.1. Australia Purpura Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.2. Australia Purpura Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.3. Australia Purpura Treatment Market, Segmentation By Cases, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Purpura Treatment Market

  • 13.1. Indonesia Purpura Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.2. Indonesia Purpura Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.3. Indonesia Purpura Treatment Market, Segmentation By Cases, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Purpura Treatment Market

  • 14.1. South Korea Purpura Treatment Market Overview
  • 14.2. South Korea Purpura Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.3. South Korea Purpura Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.4. South Korea Purpura Treatment Market, Segmentation By Cases, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Purpura Treatment Market

  • 15.1. Western Europe Purpura Treatment Market Overview
  • 15.2. Western Europe Purpura Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.3. Western Europe Purpura Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.4. Western Europe Purpura Treatment Market, Segmentation By Cases, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Purpura Treatment Market

  • 16.1. UK Purpura Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.2. UK Purpura Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.3. UK Purpura Treatment Market, Segmentation By Cases, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Purpura Treatment Market

  • 17.1. Germany Purpura Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.2. Germany Purpura Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.3. Germany Purpura Treatment Market, Segmentation By Cases, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Purpura Treatment Market

  • 18.1. France Purpura Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.2. France Purpura Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.3. France Purpura Treatment Market, Segmentation By Cases, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Purpura Treatment Market

  • 19.1. Italy Purpura Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.2. Italy Purpura Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.3. Italy Purpura Treatment Market, Segmentation By Cases, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Purpura Treatment Market

  • 20.1. Spain Purpura Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.2. Spain Purpura Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.3. Spain Purpura Treatment Market, Segmentation By Cases, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Purpura Treatment Market

  • 21.1. Eastern Europe Purpura Treatment Market Overview
  • 21.2. Eastern Europe Purpura Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.3. Eastern Europe Purpura Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.4. Eastern Europe Purpura Treatment Market, Segmentation By Cases, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Purpura Treatment Market

  • 22.1. Russia Purpura Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.2. Russia Purpura Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.3. Russia Purpura Treatment Market, Segmentation By Cases, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Purpura Treatment Market

  • 23.1. North America Purpura Treatment Market Overview
  • 23.2. North America Purpura Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.3. North America Purpura Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.4. North America Purpura Treatment Market, Segmentation By Cases, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Purpura Treatment Market

  • 24.1. USA Purpura Treatment Market Overview
  • 24.2. USA Purpura Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.3. USA Purpura Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.4. USA Purpura Treatment Market, Segmentation By Cases, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Purpura Treatment Market

  • 25.1. Canada Purpura Treatment Market Overview
  • 25.2. Canada Purpura Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.3. Canada Purpura Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.4. Canada Purpura Treatment Market, Segmentation By Cases, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Purpura Treatment Market

  • 26.1. South America Purpura Treatment Market Overview
  • 26.2. South America Purpura Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.3. South America Purpura Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.4. South America Purpura Treatment Market, Segmentation By Cases, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Purpura Treatment Market

  • 27.1. Brazil Purpura Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.2. Brazil Purpura Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.3. Brazil Purpura Treatment Market, Segmentation By Cases, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Purpura Treatment Market

  • 28.1. Middle East Purpura Treatment Market Overview
  • 28.2. Middle East Purpura Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.3. Middle East Purpura Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.4. Middle East Purpura Treatment Market, Segmentation By Cases, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Purpura Treatment Market

  • 29.1. Africa Purpura Treatment Market Overview
  • 29.2. Africa Purpura Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.3. Africa Purpura Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.4. Africa Purpura Treatment Market, Segmentation By Cases, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Purpura Treatment Market Competitive Landscape And Company Profiles

  • 30.1. Purpura Treatment Market Competitive Landscape
  • 30.2. Purpura Treatment Market Company Profiles
    • 30.2.1. Merck & Co Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.2. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.3. GlaxoSmithKline plc Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.4. Takeda Pharmaceutical Company Limited Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.5. Amgen Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Purpura Treatment Market Other Major And Innovative Companies

  • 31.1. CSL Limited
  • 31.2. Intas Pharmaceuticals Ltd.
  • 31.3. Biogen Inc.
  • 31.4. Chugai Pharmaceutical Co Ltd.
  • 31.5. Sun Pharmaceutical Industries Limited
  • 31.6. Octapharma AG
  • 31.7. Grifols S.A.
  • 31.8. GC Pharma
  • 31.9. Emergent BioSolutions Inc.
  • 31.10. Kissei Pharmaceutical Co Ltd.
  • 31.11. Ablynx N.V.
  • 31.12. Shire plc
  • 31.13. Lee's Pharmaceutical Holdings Limited
  • 31.14. Omeros Corporation
  • 31.15. KM Biologics Co Ltd.

32. Global Purpura Treatment Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Purpura Treatment Market

34. Recent Developments In The Purpura Treatment Market

35. Purpura Treatment Market High Potential Countries, Segments and Strategies

  • 35.1 Purpura Treatment Market In 2029 - Countries Offering Most New Opportunities
  • 35.2 Purpura Treatment Market In 2029 - Segments Offering Most New Opportunities
  • 35.3 Purpura Treatment Market In 2029 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer